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Ubiquitous calpains (- and m-calpain) have been re-
peatedly implicated in apoptosis, but the underlying
mechanism(s) remain(s) to be elucidated. We examined
ionomycin-induced cell death in LCLC 103H cells, de-
rived from a human large cell lung carcinoma. We de-
tected hallmarks of apoptosis such as membrane bleb-
bing, nuclear condensation, DNA ladder formation,
caspase activation, and poly-(ADP-ribose)polymerase
cleavage. Apoptosis was prevented by preincubation of
the cells with the calpain inhibitor acetyl-calpastatin
27-peptide and the caspase inhibitor Z-DEVD-fmk, im-
plicating both the calpains and caspases in the apo-
ptotic process. The apoptotic events correlated in a
calpastatin-inhibitable manner with Bid and Bcl-2 de-
crease and with activation of caspases-9, -3, and -7. In
vitro both ubiquitous calpains cleaved recombinant
Bcl-2, Bid, and Bcl-xL at single sites truncating their
N-terminal regions. Binding studies revealed dimin-
ished interactions of calpain-truncated Bcl-2 and Bid
with immobilized intact Bcl-2 family proteins. More-
over, calpain-cleaved Bcl-2 and Bid induced cytochrome
c release from isolated mitochondria. We conclude that
ionomycin-induced calpain activation promotes de-
crease of Bcl-2 proteins thereby triggering the intrinsic
apoptotic pathway.
Studies on a number of cell types, such as neurons that die
during formation of the nervous system and lymphocytes that
die during receptor repertoire selection in adults, have shown
that cells can activate built-in suicide mechanisms (1). Pro-
grammed cell death, or apoptosis, is beneficial during embry-
onic development and adult life but its dysregulation accompa-
nies the pathogenesis of many diseases (reviewed in Ref. 2).
Inappropriate increase in apoptotic cell death has been re-
ported in wasting diseases such as AIDS, neurodegenerative
disorders, and ischemic injury, whereas decreases in cell death
contribute to proliferative autoimmune diseases and tumori-
genesis. A precise description of cell death pathways and their
regulation is therefore critical to understand cell death-associ-
ated diseases and to develop therapeutic strategies.
Proteolytic enzymes of the caspase family play a central role
in initiating and sustaining the biochemical events that result
in apoptotic cell death (3). In some forms of apoptosis, the
extrinsic apoptotic pathway is initiated by activation of the
apical caspase-8 following death receptor ligation (4). In other
forms, cellular stress leads to activation of the intrinsic apo-
ptotic pathway initiated by the apical caspase-9 (5). These
pathways converge upon activation of the executioner
caspases-3 and -7. Superimposed on this minimal scheme is an
“integration model” in which both upstream and downstream
caspases as well as other proteases cooperate to regulate
apoptosis in a cell-specific manner (reviewed in Ref. 6).
The intrinsic pathway is triggered by cytochrome c release
from mitochondria (7). The mechanism by which cytochrome c
crosses the mitochondrial outer membrane is not yet known,
but the opposing actions of a group of intracellular proteins, the
Bcl-2 family proteins, critically regulate this process (8). The
Bcl-2 family has been divided into three groups based on struc-
tural similarities and functional criteria (reviewed in Ref. 9).
Group I consists of anti-apoptotic proteins, such as Bcl-2 and
Bcl-xL, which possess four short conserved Bcl-2 homology
(BH)1 domains (BH1–BH4). Group II members, exemplified by
the pro-apoptotic proteins Bax and Bak, have a similar overall
structure, containing all but the BH4 domains. Group III pro-
teins consist of a large and diverse collection of proteins, exem-
plified by the pro-apoptotic Bid and Bik, whose common feature
is the presence of the BH3 domain.
The function of calcium in apoptosis is a complex subject
involving interplay between many systems, such as the sphin-
gomyelin signaling pathway, the redox system, the stress-acti-
vated protein kinase cascade, and the calcium signaling path-
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way (reviewed in Ref. 10). Regarding this, it has been reported
that Bcl-2 family proteins may exert some of their actions by
interfering with calcium dynamics of mitochondria and endo-
plasmic reticulum (10).
Increase of intracellular Ca2 level induces apoptosis in thy-
mocytes (11), hypocampal neurons (12), and various cancer
cells via activation of calcium-dependent enzymes (e.g. Ref. 13).
Addition of a calcium ionophore such as A23187 rapidly leads
to activation of the ubiquitous calpains (14). Calpains are in-
tracellular calcium-dependent cysteine endopeptidases but are
otherwise structurally unrelated to caspases. The calpain fam-
ily members can be classified as typical calpains, which are
further divided into ubiquitous and tissue-specific calpains,
and atypical calpains (reviewed in Ref. 15). Ubiquitous calpains
occur in two isoforms, -calpain (CP) and m-calpain (mCP)
requiring micromolar or millimolar calcium concentrations for
their activation in vitro, respectively. These heterodimeric en-
zymes consist of a small regulatory subunit (30 kDa) and a
large catalytic subunit (80 kDa). In this work the term “cal-
pains” refers to endogenous ubiquitous calpains.
The physiological roles of calpains are largely unknown,
although their ubiquitous and constitutive expression strongly
suggests essential and basic functions in vivo. In particular,
connections to apoptotic processes have been suggested. For
instance, calpains may be involved, in synergy with caspases,
in the down-regulation of inositol 1,4,5-trisphosphate receptor
subtypes during tumor necrosis factor--induced apoptosis of
human T lymphoma cells (16). Cross-talk between calpains and
caspases has been reported in the activation of caspase-12 (17),
during etoposide-induced apoptosis in T cells (18), and during
apoptosis of neuronal cells induced by a prion protein fragment
(19). Synergistic involvement of calpain and the proteasome in
apoptosis of human neutrophils has also been reported (20).
Other authors (21) have suggested that calpains are activated
via caspase-mediated cleavage of calpastatin during initiation
of apoptotic execution. Finally, the transcription factor p53 is
cleaved by ubiquitous calpains, suggesting a link between cal-
pain activation and p53-dependent apoptosis (22).
Here we report that the calcium ionophore ionomycin pro-
motes apoptosis in LCLC 103H cells, a cell line derived from a
human large cell lung carcinoma (23). These cells represent an
excellent system to study the effects of calcium increase in-
duced by ionomycin, helping us to elucidate the pathways re-
sponsible for calcium-induced apoptosis.
EXPERIMENTAL PROCEDURES
Materials—Human CP was isolated from erythrocytes according to
Ref. 24; mCP was supplied by Calbiochem. Recombinant Bcl-2 proteins
were purified as described elsewhere. Actin was from ICN Biomedicals.
The following antibodies were used: anti-mouse Bax, anti-cytochrome c,
anti-human Bid (BD PharMingen), anti-PARP (Biomol), anti-human
Bcl-xL (Kamiya Biomedical Co.), anti-human Bcl-2 (Dako), anti-caspase
8 (BD PharMingen), and anti-actin (Sigma). The fluorogenic substrates
Ac-DEVD-amc and Suc-LLVY-amc were purchased from Bachem.
AC27P was from Sigma; methylated Z-DEVD-fmk was from Alexis; and
lactacystin was from Calbiochem. All other reagents were of the highest
purity commercially available.
Cell Culture—For routine cell culture RPMI 1640 medium (Invitro-
gen) was supplemented with 10% fetal calf sera (Sigma), 0.6% L-gluta-
mine. Transfection was carried out using the FuGENETM 6 Reagent
(Roche Molecular Biochemicals) according to the general protocol sug-
gested by the manufacturer but applying the following reagent ratios: 1
g of DNA, 1.5 l of FuGENETM 6 Reagent, 33 l of serum-free RMPI
1640. Cells were maintained at 37 °C in a humidified 5% CO2 atmo-
sphere. LCLC 103H cells (DSMZ ACC 384), a clone stably expressing
the chimeric protein histone H2A.i-ECFP, and LCLC 103H cells tran-
siently overexpressing GFP (pNT-GFP, Invitrogen) were used in this
study. When being subcultured, cells were lifted using a trypsin/EDTA
solution (Invitrogen).
Monitoring of Nuclear and Cellular Changes—Cells were cultured on
inner diameter 4.2-cm coverslips (Langenbrick) and treated with the
indicated insult. For fluorescence microscopy, coverslips were mounted
on POC chambers (PeCon), kept at 34–36 °C and 5% CO2 in the micro-
scope (Axiovert S100 TV, Zeiss) equipped with objectives, Fluor 40/1.3
oil Ph2 and Neofluar 63/1.25 oil Ph3, filter wheels, and shutters (Ludl),
Orca 4742-95 CCD camera (Hamamatsu), and controlled by OpenLab
software (Improvision). Filter systems were from Chroma Technologies;
GFP excitation 490/20 nm, beam splitter 505 nm, emission 535/40 nm;
ECFP excitation 470/30 nm, beam splitter 470/50 nm  565/80 nm,
emission 560/30 nm. For presentation, images were contrast-enhanced
and “false-colorized” with the OpenLab software.
Apoptotic DNA Ladder Detection—Total DNA was isolated (25), sep-
arated on 2% agarose gels, and stained with ethidium bromide.
Isolation of Cytoplasmic Proteins—Cytoplasmic extracts were pre-
pared by Dounce homogenization and differential centrifugation as
described previously (26). Samples were mixed with sample buffer,
heated for 2–5 min at 95 °C, and electrophoretically resolved on SDS-
Tricine (16%) gels. Finally, samples were transferred to nitrocellulose
membranes (Schleichler & Schuell) and probed against the indicated
antibodies. Antibody complexes were detected with anti-mouse IgG or
anti-rabbit horseradish peroxidase-linked IgG from New England Bio-
labs using ECL (Amersham Biosciences). Protein content was assayed
by the bicinchoninic acid method (27).
Affinity Labeling—Aliquots of cytosolic proteins were incubated for
30 min at 37 °C with 2 M biotin-VAD-fmk (Enzyme System Products).
After incubation, extracts were diluted to 0.5 g/l in 4-fold concen-
trated SDS-Tricine sample buffer. Electrophoresed samples were trans-
ferred to nitrocellulose membranes, probed with peroxidase-labeled
streptavidin, and visualized by Super Signal West Pico chemilumines-
cent substrate (Pierce).
Calpainolysis of Bcl-2 Proteins in Vitro—Recombinant Bcl-2 (4.2 M),
Bcl-xL (4.5 M), Bid (4.8 M), and actin (2.4 M) were incubated with
purified CP or mCP for 1 h at room temperature at a 1:100 enzyme/
substrate molar ratio in calpain assay buffer (50 mM Tris-HCl, 100 mM
NaCl, pH 7.5, 20 mM dithiothreitol, 5 mM CaCl2). Reactions were
stopped by addition of 10 mM EDTA and iodoacetamide, separated on
SDS-Tricine (16%) gels, and either visualized by Coomassie Blue stain-
ing or transferred to nitrocellulose or polyvinylidene difluoride mem-
branes. Samples for Biacore experiments were prepared with a 1:10
molar calpain/protein ratio. The purified recombinant proteins and
calpainolytic products were subjected to N-terminal amino acid se-
quencing on a PROCISETM protein sequencer (Applied Biosystems
Inc.).
Cytochrome c Release in Vitro—Mitochondria were isolated from rat
heart according to the procedure described previously (28). Mitochon-
drial protein content was estimated by preincubating an aliquot of this
preparation with 5% Triton X-100, and thereby the released cytochrome
c was assumed to represent the total mitochondrial cytochrome c con-
tent. To analyze cytochrome c-releasing activity of intact and calpain-
cleaved Bcl-2 proteins, aliquots of rat mitochondria corresponding to 15
g of protein were incubated with 10 l of the following samples
prepared according to the calpainolysis protocol explained above: (i)
Bcl-2 protein preincubated with Ca2, (ii) CP preincubated with Ca2,
and (iii) Bcl-2 protein preincubated with CP and Ca2, according to
Ref. 29. The final protein concentrations are as follows: Bcl-2, 1.0 nM;
Bcl-xL, 1.8 nM; and Bid, 10.1 nM. Gels were transferred to nitrocellulose
membranes, probed with anti-cytochrome c antibody, and analyzed by
densitometry (Scion Image).
Biomolecular Interaction Analysis of Bcl-2 Proteins—Interactions
between Bcl-2 family proteins and their calpainolytic products were
analyzed in a Biacore 2000 instrument (Biacore AB) essentially as
described previously (30). Bcl-xL, Bax, Bcl-2, and Bid were immobilized
on CM5 sensor chips via amine coupling (2000–4000 resonance units).
Calpainolytic reaction mixtures of Bid, Bcl-2, and Bcl-xL were prepared
as described above, except that after addition of EDTA the pH was
adjusted to 6.0 (Bcl-2) or 7.5 (Bid, Bcl-xL) and diluted 8-fold with
running buffer (50 mM acetate, 150 mM NaCl, 3.4 mM EDTA, 0.005%
Tween 20, pH 4.0 for Bcl-xL and Bid, 50 mM phosphate, 3.4 mM EDTA,
0.005% Tween 20, pH 6.4 for Bcl-2). Analytes (70 l at 0.5–2.0 M) were
injected at a flow rate of 10 l/min. Sensorgrams of ethanolamine
blanks were used for subtraction of changes in the bulk refractive index.
Between sample injections, the sensor chips were regenerated with 50
mM phosphate (pH 6.8) and 4 M guanidine HCl. The sensorgrams were
analyzed using the BIAevaluation 3.1 software.
Protease Activity in Living Cells—Calpain- or caspase-like activities
in whole cells were measured with the fluorogenic substrates Suc-
LLVY-amc (160 M) or Ac-DEVD-amc (200 M), respectively. The sub-
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strates ionomycin, etoposide, and AC27P were mixed in the appropriate
HEPES-buffered serum-free growth media. LCLC 103H cells were
plated on 24-well plates (105 cells/well) and preincubated with the
substrate for 30 min at 37 °C in a humidified 5% CO2 incubator. Sub-
strate hydrolysis at 37 °C was monitored using a fluorescence reading
system (Fluoroskan ascent) set to 355  20 nm for excitation and 460 
20 nm for emission. Fluorescence readings were collected every 5 min
(up to 400 min), before and after addition of ionomycin, and after
preincubation of the cells for 1 h at 37 °C with 50 M AC27P or 20 M
of Z-DEVD-fmk.
FACS Analysis of Apoptotic Cells—Cell viability was assessed by flow
cytometry simultaneously monitoring annexin V binding and pro-
pidium iodide uptake. LCLC 103H cells were plated on inner diameter
10-cm culture plates and treated at 37 °C with the indicated inhibitor/
FIG. 1. Induction of cell death and calpain activation in LCLC 103H cells by ionomycin. A and B show the time course of cell death after
addition of ionomycin to LCLC 103H cells overexpressing GFP either without (A) or after preincubation with 50 M AC27P (B). Left (a, c, and e)
and right lanes (b, d, and f) represent phase contrast and fluorescence images, respectively. C, ectopic expression of GFP does not trigger apoptosis
in LCLC 103H cells. Superimposition of phase contrast and fluorescence images before (a) and 23 h after addition of ionomycin (b). A, bars
represent 50 m; B, 5 m; C, 50 (a) and 25 m (b). D, increase of intracellular calcium concentration upon ionomycin addition to LCLC 103H cells.
Cells were loaded with Fura-2 for 30 min and treated with 2 M ionomycin as explained under “Experimental Procedures.” Calcium concentration
changes monitored in six different cells are represented in dark or light blue, yellow, pink, violet, and brown. E, AC27P-inhibitable Suc-LLVY-
amc-hydrolyzing activity increases after addition of 2 M ionomycin to LCLC 103H cells. Cleavage rates of the fluorogenic substrate Suc-LLVY-amc
(slopes of the progress curves, F 460 nm/min, in arbitrary units) were calculated from amc-fluorescence recorded between 5 and 170 min (linear
phase of substrate cleavage) as the mean of three experiments (S.D. 10%, indicated by bars). **, differences to activity after preincubation with
AC27P (2nd column, dashed line) statistically significant (p  0.01).
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insult, resuspended in 2 ml of annexin V binding buffer, and finally
treated with annexin V-fluorescein and propidium iodide (9:1) for 5 min
at room temperature. Fluorescence of 20000 cells was measured with
a FACS-Calibur Sort (BD PharMingen) through a 530/30 bandpass
filter to monitor annexin-fluorescein-phosphatidylserine binding and
through a 585/42 filter to monitor propidium iodide uptake.
Measurement of Free Calcium Concentrations—Free calcium concen-
trations in LCLC 103H cells were determined before and after adding 2
M ionomycin. These measurements and the calibration of Fura-2 flu-
orescence was performed according to standard protocols (31). Briefly,
cells were loaded for 1 h with 5 M Fura-2 AM diluted in FluoronicR
F-127. Coverslips were rinsed with a solution containing 20 mM
HEPES, 5.6 mM glucose, 137 mM NaCl, 0.8 mM KCl, 0.5 mM CaCl2, 1.0
mM MgCl2, 2 mM EDTA, pH 7.4, placed in an imaging chamber, and
mounted in a platform at 37 °C on the stage of a Nikon Diaphot. Fura-2
was excited at alternating wavelengths of 340- and 380-nm using a
75-watt xenon light source and a filter wheel (Ludl). Emitted wave-
lengths passed through a 510-nm filter cube set before detection by an
enhanced CCD camera. Saturating calcium concentrations were meas-
ured after rinsing and preincubation of the cells with a solution of 10
mM CaCl2 in 20 mM HEPES, pH 7.4, containing 5.6 mM glucose, 137 mM
NaCl, 0.8 mM KCl, 1.0 mM MgCl2, 2 mM EDTA, and two subsequent
additions of 2 M ionomycin with 5-min interval between them. After
that, absence of calcium was measured by adding 2 ml of 80 mM EGTA,
pH 8.0. Data were stored and processed using the IonWizard software.
RESULTS
Ionomycin Induces Apoptosis in LCLC 103H Cells—In the
course of calpain localization studies, we observed that LCLC
103H cells overexpressing the catalytic subunit of -calpain
rapidly underwent cell death after treatment with ionomycin
(not shown). To monitor this process in cells not overexpressing
calpain, we labeled LCLC 103H cells transiently with GFP or
stably with a histone-ECFP chimera. The first signs of ionomy-
cin-induced cell death were detected 3 h after addition of the
ionophore. We observed typical hallmarks of apoptosis, includ-
ing cell blebbing and fragmentation, which were prevented for
24 h by preincubation with the selective calpain inhibitor
AC27P (Fig. 1, A and B). Untreated cells overexpressing GFP
(Fig. 1C) or the chimeric-ECFP protein (not shown) were not
impaired in their vitality, ruling out that ectopic expression of
either protein is cytotoxic for this cell line.
Addition of 2 M ionomycin to LCLC 103H cells caused an
FIG. 2. Hallmarks of apoptosis in
ionomycin-treated LCLC 103H cells.
Nuclear changes in LCLC 103H cells sta-
bly overexpressing H2A.i-ECFP after
treatment with 2 M ionomycin (A), 68 M
etoposide (B), or 2 M ionomycin after pre-
incubation with 50 M AC27P (C). Left (a,
c, and e) and right lanes (b, d, and f)
represent phase contrast and fluores-
cence images, respectively. Bars repre-
sent 25 m. D and E, DNA ladder forma-
tion in ionomycin-treated LCLC 103H (D)
and COS 7 cells (E). F, Western blots of
cell lysates from LCLC 103H cells probed
with anti-PARP and anti-actin antibod-
ies. Endogenous intact proteins and
cleaved PARP (85 kDa) are indicated by
solid and dashed lines, respectively.
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instantaneous increase in intracellular Ca2 concentration
from 50 to 180 nM (Fig. 1D). Remarkably, calcium concentra-
tions were raised transiently to 0.8–1.5 M. Concomitantly,
calpains were activated, as reflected by almost a double in-
crease of Suc-LLVY-amc cleavage inhibited by AC27P (Fig.
1E). In addition, nuclear condensation was detected in the
histone-ECFP-labeled cells 3 h after addition of ionomycin (Fig.
2A), and it was inhibited by preincubation with AC27P (Fig.
2C). DNA and protein analysis in ionomycin-treated cultures
revealed DNA fragmentation (Fig. 2D) and PARP cleavage to
an 85-kDa fragment typical of caspase-mediated apoptosis (Fig.
2F). The same observations were made in etoposide-treated
LCLC 103H cells (Fig. 2B) and in COS 7 cells after ionomycin
addition (Fig. 2E), suggesting an apoptotic process, although its
onset was delayed in comparison to ionomycin-treated LCLC
103H cells. These findings demonstrate that ionomycin induces
apoptosis in these cells in a calpain-dependent manner.
Caspase Involvement in Ionomycin-induced Apoptosis—Flow
cytometric analysis of fluorescein-labeled annexin V binding
and propidium iodide uptake were used to quantify early apo-
ptotic cells. Three hours after addition of ionomycin, the per-
centage of early apoptotic cells approximately doubles (Fig.
3A). Necrosis could be detected in 1–5% of the ionomycin-
treated cells (not shown) as supported by simultaneously pos-
itive fluorescein labeling and propidium iodide uptake. Apo-
ptosis of LCLC 103H cells was inhibited by preincubation with
AC27P or the caspase inhibitor Z-DEVD-fmk. In contrast, apo-
ptosis could not be prevented by preincubation of cells with the
proteasome inhibitor lactacystin. Caspase activation in whole
cells was followed by monitoring the increase in activity
against Ac-DEVD-amc following ionomycin treatment. In ad-
dition, we evaluated the effect of preincubating the cells with
either AC27P or Z-DEVD-fmk (Fig. 3B). Cleavage of Ac-DEVD-
FIG. 3. Caspase activation in ionomycin-induced apoptosis of LCLC 103H cells. A, effect of calpain and caspase inhibitors on ionomycin-
induced apoptosis. Cells treated with the indicated insults/inhibitors had annexin V-fluorescein and propidium iodide added before being counted
and sorted by FACS as described under “Experimental Procedures.” % apoptotic cells represents the percentage of cells positive for phosphati-
dylserine externalization and negative for propidium iodide related to the total amount of cells. B, caspase activity measured in LCLC 103H cells
after 30 min of incubation at 37 °C with the fluorogenic substrate Ac-DEVD-amc (F460 nm/min, in arbitrary units). , spontaneous activity; Ion,
activity after addition of 2 M ionomycin; Eto, activity after treatment with 68 M etoposide; DEVD-fmk, AC27P, and lactacystin, activities in cells
preincubated with the corresponding inhibitors before addition of 2 M ionomycin. All experiments were performed in triplicate; S.D. is indicated
by bars. **, difference to non-treated cells (, dashed line) statistically significant (p  0.01). C, presence of active caspases-3, -7, and -9 in the
cytosol of apoptotic cells. Cytosolic proteins were affinity-labeled with biotin-VAD-fmk. Biotinylated recombinant caspases 3, -7, -8, and -9 were
applied as standards (see “Results” for explanation of bands I–III). Notice that active species are absent in cytosolic lysates of cells pretreated with
AC27P. D, Western blot using an anti-caspase-8 antibody showing that pro-caspase-8 is not activated in ionomycin-induced apoptosis.
FIG. 4. Ionomycin-induced death of LCLC 103H cells is accom-
panied by cytochrome c release and changes in the concentra-
tions of Bcl-2 proteins. A, ionomycin-induced cytochrome c release in
vivo. Western blots for cytochrome c and actin detection. B, processing
of endogenous Bcl-2, Bcl-xL, Bid, Bax, and actin in vivo. Western blots
for Bcl-2, Bcl-xL, Bid, Bax, and actin (indicated by solid lines). Actin was
neither processed during ionomycin-induced apoptosis nor in etoposide-
treated cells.
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amc predominantly reflects the activity of executioner
caspase-3, although other caspases may also contribute to the
increase in activity (32). Caspase activation occurs 3 h after
ionomycin treatment and is inhibited to a similar extent by
AC27P and by Z-DEVD-fmk.
To delineate more completely the spectrum of caspases acti-
vated in LCLC 103H cells, cytosolic extracts were incubated
with the affinity label biotin-VAD-fmk. Three discrete bands
termed I (35 kDa), II (25 kDa), and III (17 kDa) were
detected 3 h after the addition of 2 M ionomycin (Fig. 3C). The
use of antisera to detect cleavage of caspases-3, -7, and -9 is
indicative of activation but is not definitive because all of the
active enzymes are expected to be complexed in vivo by mem-
bers of the IAP family of caspase inhibitors (33, 34). Therefore,
we sought to use a more direct assay for the activity of individ-
ual caspases. The mobility of the large subunits of active
caspases detected via biotin labeling was compared with the
mobility of the corresponding subunits of recombinant human
caspases (Fig. 3C). In SDS-Tricine gels, the lower band III
migrates as the large subunit of the executioner caspase-3,
with band II migrating similar to both recombinant caspases-7
and -8. Finally, band I is consistent with alternatively pro-
cessed caspase-9 (equivalent to the 35-kDa band seen in Ref.
35). No active caspases were detected in cytosol from either
untreated or AC27P-treated cells (Fig. 3C). Faint bands of
higher molecular masses were also observed and either repre-
sent zymogens with slight activity (36) and/or the 37-kDa band
seen for processed caspase-9 in Ref. 35. We could not detect
caspase-8 processing and therefore no mature enzyme in any of
the lysates (Fig. 3D). Taken together, these results indicate
that ionomycin treatment is associated with activation of mul-
tiple caspases via the intrinsic (mitochondrial) pathway and
furthermore strongly suggest that caspases-3, -7, and -9 are
activated downstream of calpain after ionomycin treatment.
Ionomycin-induced Cytochrome c Release and Bcl-2 and Bid
Decrease—During ionomycin-induced cell death we observed a
marked release of cytochrome c from mitochondria 3 h after
addition of the ionophore (Fig. 4A). Similar amounts of cyto-
chrome c were released upon treatment of the cells with 68 M
etoposide. In contrast, no cytoplasmic cytochrome c was de-
tected either in lysates from wild type LCLC 103H cells or in
cells preincubated with AC27P before addition of ionomycin.
Next, we aimed to identify calpain substrates associated
with the observed cell death processes. We had described
previously (37) that caspases-3 and -9 are not directly acti-
vated by calpain, yet another report (38) concluded that cal-
pains are able to activate procaspase-7 in apoptosis during
clonal expansion of B cells. In our hands, low -calpain con-
centrations produced limited cleavage of recombinant pro-
caspase-7, truncating its N terminus at positions Phe-36 and
Met-45 (Phe-129 and Met-138 in the caspase-1 numbering
system). However, these cleavages are irrelevant for genera-
tion of an active caspase, as revealed in the recent structures
of human procaspase-7 (39, 40); and accordingly no activity
against the caspase-7 substrate Ac-DEVD-amc was observed
(not shown). At higher calpain concentrations both caspase-3
and -7 zymogens were completely degraded, and at no time
was caspase activity detected (not shown).
In the absence of evidence for direct caspase processing, we
explored whether calpains could cleave mitochondrial regula-
tors of cytochrome c release, particularly members of the Bcl-2
family. Indeed, we noted differences in the concentrations of
endogenous Bcl-2, Bcl-xL, Bid, and Bax during ionomycin-in-
duced cell death in LCLC 103H cells (Fig. 4B). Two hours after
ionomycin treatment, the cytosolic amounts of Bcl-2 and Bcl-xL
decreased remarkably. Only 1 h later intact Bcl-2 could no
longer be detected, and intact Bcl-xL as well as Bid were di-
minished, whereas no Bax was degraded up to 3 h. Ionomycin-
induced Bcl-2 and Bid decrease was prevented by preincuba-
tion with AC27P. Curiously, the intensity of the Bcl-2 band was
highest in cells pretreated with AC27P, suggesting that this
calpain inhibitor stimulates Bcl-2 expression (Fig. 4B), consist-
ent with previous reports (41) that calpeptin pretreatment
prior to A23187 prevented -calpain overexpression and de-
creased the Bax/Bcl-2 ratio.
Bcl-2 Family Proteins Are Calpain Substrates in Vitro—The
results discussed above suggested that activated calpains may
cleave several Bcl-2 proteins. To verify this hypothesis, recom-
binant Bcl-2 proteins were incubated with purified human m-
and -calpain as described under “Experimental Procedures.”
Fig. 5 shows that -calpain cleaves recombinant Bcl-2, Bid, and
Bcl-xL at unique sites in vitro and generates the following
truncated proteins: Bcl-2/p15, Bid/p13, and Bcl-xL/p18 (named
according to their approximate apparent molecular masses;
similar results were obtained with mCP). Proteolysis depended
on the presence of calpain and was prevented by the irrevers-
ible calpain inhibitor Z-LLY-CHN2. Initial cleavage of Bcl-2,
Bid, and Bcl-xL was rapid, occurring 5 min after reaction start
(not shown). The cleavage sites identified after incubation for
1 h are summarized in Table I and Fig. 6. After longer incuba-
tion times, additional cleavage sites were found in Bcl-2 behind
His-94, Thr-96, and Arg-98. The cleavage products were not
detected by the commercially available antibodies against the
Bcl-2 family proteins used in this work (not shown).
Calpain-cleaved Bcl-2 and Bid Induced Cytochrome c Release
from Isolated Mitochondria—Isolated mitochondria from rat
cardiac muscle were incubated either with calpain alone, the
FIG. 5. Calpainolysis of Bcl-2 family proteins in vitro. SDS-
Tricine (16%) gels showing the effects of -calpain on Bcl-2, Bid, Bcl-xL,
and actin. The intact recombinant proteins (solid lines) and their cleav-
age products (Bcl-2/p15, Bid/p13, and Bcl-xL/p18; dashed lines) were
identified by N-terminal sequencing (right margin). Results are repre-
sentative of five replicas. Notice that actin was not cleaved by calpain in
vitro.
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Bcl-2 proteins alone, or with the calpain-treated Bcl-2 proteins.
Mitochondria incubated with either -calpain, caspase-8, Bcl-2,
or Bid showed only very low cytochrome c release. In striking
contrast, incubation of mitochondria with calpain-truncated
Bcl-2 or Bid induced substantial or almost complete release of
cytochrome c when compared with total mitochondrial cyto-
chrome c content (Fig. 7A). Remarkably, calpain-truncated Bid
released cytochrome c to a similar degree as caspase-8-cleaved
Bid. In contrast, only minimal differences were detected in the
amounts of cytochrome c released by calpain-truncated or in-
tact Bcl-xL (Fig. 7A).
FIG. 6. Ribbon plots of Bcl-2 family members indicating cal-
pain cleavage sites. Coordinates were taken from the deposited files,
Protein Data Bank codes 1G5M (Bcl-2/Bcl-xL chimera), 2BID (Bid), and
1MAZ (Bcl-xL). A Bcl-2 model was constructed by replacing the artificial
loop sequence of the Bcl-2/Bcl-xL chimera by the correct sequence found
in human Bcl-2. The BH3 domains of the three proteins were superim-
posed using Turbo-FRODO, and the images were made with SETOR.
All structures are shown at the same scale. Arrows point to the unique
calpain cleavage sites found within the corresponding Bcl-2 family
protein. Other cleavage sites are also indicated (see also Table I).
FIG. 7. Effect of calpainolysis on Bcl-2 family proteins. A, cal-
pain-cleaved Bcl-2 and Bid induce cytochrome c release from isolated
mitochondria. Mitochondria were incubated for 40 min at 30 °C either
in the presence or absence of Bcl-2 proteins and calpain as explained
under “Experimental Procedures.” The supernatants (released cyto-
chrome c) and pellets (mitochondrial cytochrome c) were resolved on
SDS-Tricine (16%) gels followed by Western blotting using an anti-
cytochrome c antibody. Casp, caspase. B, binding of calpain-cleaved Bid,
Bcl-2, and Bcl-xL to their immobilized intact counterparts is dimin-
ished. Biacore results obtained with two chips loaded with the immo-
bilized ligands Bcl-xL, Bax, Bcl-2, and Bid. Fractional binding surface
plasmon response (resonance units) of the calpain-cleaved analytes Bid
(gray), Bcl-2 (white), Bcl-xL (black) expressed as a fraction of the re-
sponse of the intact analytes, after subtraction of the response of cal-
pain. All experiments were conducted in triplicate.
TABLE I
Summary of cleavage sites identified in Bcl-2 family proteins
Bcl-2 protein Proteinase Cleavage site Ref.
Bcl-xL Caspase-3 Asp-61, Asp-76 63
Bcl-xL DEVD-cho-sensitive enzymes Asp-61 61
Bcl-xL m-calpain Ala-60 17
Bcl-xL - and m-calpain Glu-42 This work
Bcl-2 HIV aspartic protease Phe-112 64
Bcl-2 Caspase-3 Asp-34 56
Bcl-2 Z-VAD-fmk inhibitable protease Asp-34 65
Bcl-2 - and m-calpain Gln-73 This work
Bid Caspase-8 Asp-59 66
Bid Granzyme B Asp-75 67
Bid Lysosomal proteinases Arg-65 29
Bid Calpain Gly-70 60
Bid - and m-calpain Tyr-54 This work
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Calpain Cleavage of Bcl-2 Family Proteins Affects Their Ho-
mo- and Heterophilic Interactions—Various Bcl-2 family pro-
teins have been shown to influence mitochondrial integrity via
poorly understood processes that involve both homo- and het-
erodimerization (42, 43). We applied surface plasmon reso-
nance to monitor the interactions between intact and -cal-
pain-cleaved Bcl-2 proteins in vitro. Intact Bcl-2 proteins were
coupled to CM5 chips as described under “Experimental Pro-
cedures” and were used for Biacore binding studies. Cleavage
sites within the calpain-cleaved Bcl-2 proteins were verified by
N-terminal amino acid sequencing and correspond to those
described above. Binding of calpain-treated Bcl-2 and Bid to all
four intact Bcl-2 family proteins immobilized on chips was
significantly reduced (Fig. 7B). In contrast, binding of calpain-
cleaved Bcl-xL to the Bcl-2 family proteins was unchanged or
moderately enhanced.
DISCUSSION
Two cytosolic proteolytic systems are capable of producing
limited cleavage of endogenous proteins, the caspases and the
calpains. Although it is well established that several caspases
are involved in, if not essential for, apoptosis (4, 44), the phys-
iologic role of the calpains is much less clear (45). Ablation of
the common non-catalytic 30-kDa subunit of - and m-calpain
causes embryonic lethality in mice, pointing to essential func-
tions of the enzymes (46). A number of studies have shown that
calpain activation precedes cell death induced by different ap-
optotic stimuli in various cell systems (see e.g. Refs. 47 and 48).
Therefore, we set out to dissect the involvement of ubiquitous
calpain in a calcium-induced apoptotic pathway. The calpains
are not able to produce the apoptotic phenotype on their own,
but they presumably utilize the existing latent death machin-
ery common to most nucleated metazoan cells. Previous work
(37), confirmed here, has demonstrated that calpains are not
able to activate caspases directly, so we sought other possible
entry points into the apoptotic pathway. As crucial endogenous
regulators of the intrinsic apoptotic pathway (43), Bcl-2 family
proteins were likely targets.
Here we present evidence that ionomycin-activated calpain,
as a consequence of calcium increase, triggers apoptosis in a
large cell lung carcinoma cell line concomitantly with Bcl-2 and
Bid decreases. Ionomycin-induced decreases in Bcl-2 and Bid
levels correlated in a calpastatin-inhibitable manner with cy-
tochrome c release, caspase activation, and PARP cleavage.
Thus it appears that caspase activation proceeds through the
intrinsic (mitochondrial) apoptotic pathway, with an involve-
ment of Bcl-2 family members. Related to our results, a spa-
tially and temporally regulated cascade has been proposed in a
traumatic axonal injury model, in which calpain activation
triggers intracellular changes involving release of cytochrome c
from mitochondria, followed by activation of procaspase-3 (49).
Recently, it has been reported that calpain was activated in
myocytes after superfusion with sodium-free solution when the
intracellular calcium concentration was raised to 0.45 M (50).
Consistent with these results, we report here that calpain
activation triggered by transient calcium concentration in-
creases to 0.8–1.5 M, induced by addition of 2 M ionomycin.
Increase of AC27P-inhibitable Suc-LLVY-amc hydrolyzing
activity after addition of ionomycin strongly suggests ionomy-
cin-induced activation of calpain. Suc-LLVY-amc hydrolyzing
activity that was not inhibited by AC27P could be a conse-
quence of other proteolytic activities such as those of the lyso-
somal cathepsins B and L. Papain and the papain-like lysoso-
mal cysteine proteinases are also able to cleave this fluorogenic
substrate in vitro (51).2 Interestingly, the Suc-LLVY-amc hy-
drolyzing activity decreases after preincubation with AC27P
and further treatment with ionomycin (see Fig. 1E), suggesting
the decrease of some proteolytic activities as a consequence of
apoptosis induction.
The rules governing the specificity of calpains remain un-
clear. Substrate recognition seems to be determined by the
overall three-dimensional structure rather than by particular
sequence motifs. Most calpain substrates are proteolyzed in a
restricted manner (52), suggesting that limited cleavage may
modulate the function of these substrates. Consistent with this
is our observation that ubiquitous calpains cleaved Bcl-2, Bcl-
xL, and Bid preferentially at single sites in vitro.
Bcl-2 proteins may regulate apoptosis either through pro-
tein-protein interactions or through formation of pores in lipid
membranes (42). The members of the Bcl-2 family can het-
2 I. Assfalg-Machleidt, S. Gil-Parrado, N. Schaschke, and W.
Machleidt, manuscript in preparation.
FIG. 8. Hypothetic mechanism of
calpain involvement in ionomycin-
induced apoptosis of LCLC 103H
cells. The intrinsic pathway (darker
shading) responds primarily to cellular
stress (ionizing radiation, cytotoxic drugs,
etc.) with mitochondria acting as impor-
tant integrators. Ionomycin-activated cal-
pains cleave Bcl-2 and Bid (indicated by
dashed arrows), triggering cytochrome c
release and hence the intrinsic apoptotic
pathway. The “no symbol” stands for the
diminished interactions between Bax and
calpain-cleaved Bcl-2. Apaf-1, apoptotic
protease activating factor 1.
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erodimerize with other family members, for example Bcl-2 and
Bax form heterodimers (53) that block apoptotic processes (54).
Furthermore, x-ray crystallographic analysis has shown that
the BH1/2/3 domains of Bcl-xL form a surface-exposed hydro-
phobic groove (reviewed in Ref. 42), which docks the BH3
domains of pro-apoptotic binding partners such as Bax. We
found that the intact proteins, Bcl-2 and Bid, but not their
calpain-truncated forms, were able to homo- and heterodimer-
ize to similar extents (see Fig. 7B). The sequential cleavages of
Bcl-2 observed in vitro in this work point to significant confor-
mational changes of Bcl-2 induced by cleavage at the primary
calpain cleavage site, Gln-73, presumably causing dissociation
of pro-apoptotic proteins such as Bax. Dissociation of Bax/Bcl-2
dimers would allow their translocation to the mitochondria
(55), thus triggering the intrinsic apoptotic pathway.
Calpain-truncated Bcl-2 and Bid were able to release cyto-
chrome c from isolated mitochondria. In contrast, we did not
detect significant differences between cytochrome c release in-
duced either by intact or calpain-truncated Bcl-xL. It is note-
worthy that removal of the N-terminal domain of Bcl-2, either
by BH4 deletion or by caspase cleavage, converts Bcl-2 from an
anti- to a pro-apoptotic molecule (56).
The cytosolic amounts of Bcl-2 and Bid decrease after iono-
mycin addition. These decreases are inhibited by AC27P sug-
gesting (i) cleavage of the proteins by calpain or by calpain-
induced proteases, (ii) the induction of a fast turnover of the
proteins, and (iii) down-regulation of the Bcl-2 protein expres-
sion. By taking into account that this is not a long term process
as expected for translation/modification events and, regarding
the in vitro calpainolysis results (see Fig. 5), it is likely that
calpain mediates ionomycin-induced apoptosis by direct cleav-
age of Bcl-2 proteins, such as Bcl-2 and Bid. We do not rule out
that, once generated, these calpain-cleaved products could be
likely targets of rapid turnover pathways like the proteasome
as part of a survival attempt of the cell.
Also of relevance to this study, Bcl-2 may mediate some of its
anti-apoptotic actions by modifying the way in which or-
ganelles such as the ER and mitochondria respond to varia-
tions in Ca2 concentration (57). In normal cells, Bcl-2 may
modify the Ca2 properties of the ER (58) and the mitochondria
(59) mainly by regulating the ER calcium concentration and
thus preserving the intracellular Ca2 balance. Therefore, it is
conceivable that calpain could target Bcl-2 under certain stress
conditions as part of a calcium regulatory or transduction path-
way. A recent study (60) indicates that calcium influx after
reperfusion following ischemia leads to calpain activation in
rabbit hearts and that activated calpains cleave Bid to a frag-
ment that promotes cytochrome c release. Cleavage of Bcl-2/Bid
may in turn stimulate further calpain activation, resulting in a
positive feedback activation loop.
Regardless of the mechanism Bcl-2 proteins use to induce
apoptosis, proteolytic cleavage seems to be important. The vast
majority of cleavage sites identified in Bcl-2 proteins map to
highly flexible “bait loops” connecting BH4 and BH3 domains
(Fig. 6 and Table I). Such regions are excellent targets for
proteolysis, thus allowing cells to respond rapidly to adventi-
tious and potentially damaging intracellular proteolytic activ-
ity by triggering the in-built apoptotic suicide program. Cleav-
age of the extended loop segments of Bcl-xL (61) and Bcl-2 (56)
by caspases has been reported previously to accelerate cyto-
chrome c release in vitro or decrease viability. In the current
work, cleavage of Bcl-xL was also induced by ionomycin in vivo
but was not prevented by preincubation of the cells with
AC27P.
Caspases are activated after ionomycin addition and down-
stream of calpains, as AC27P inhibition of Ac-DEVD-amc
cleavage activity suggests. We detected several polypeptide
species by affinity labeling with biotin-VAD-fmk in LCLC 103H
cells undergoing ionomycin-induced apoptosis. These polypep-
tides correspond to the large subunits of activated caspases-3,
-7, and –9. The probable contribution of caspase-8 was ruled
out because conversion of the 55-kDa zymogen was not ob-
served. This provides the first direct evidence that multiple
caspases are activated during apoptosis in LCLC 103H cells
treated with ionomycin. Together with the results of in vivo
and in vitro experiments with Bcl-2 proteins, this finding sug-
gests a calpain-induced, cytochrome c-mediated activation of
procaspase-9, which then amplifies the cascade through the
activation of downstream caspases-3 and -7 (as reviewed in Ref.
44). These results are consistent with those obtained by etopo-
side-induced apoptosis in T cells (18). This mechanism is inde-
pendent of the 20 S proteasome, because preincubation of the
cells with lactacystin could not inhibit ionomycin-induced phos-
phatidylserine externalization. We emphasize that our results
do not exclude the involvement of other proteases like
caspase-12 and cathepsins L or B in this ionomycin-induced
apoptotic pathway (17, 29) downstream of calpain. Upstream
there appears to be no reason to implicate additional proteases
because AC27P is highly specific for calpains (62),2 and the
lysosomal localization of cathepsins makes them less likely to
trigger apoptosis.
The above discussed results can be integrated into the gen-
erally accepted model of apoptosis induction (Fig. 8): An in-
crease in the intracellular calcium concentration results in the
activation of ubiquitous calpains, which then truncate Bcl-2
family proteins. In particular, activated calpains cleave Bcl-2,
resulting in the death-promoting molecule and allowing the
translocation of Bax (or itself) to the mitochondria. Bid is also
cleaved and presumably also translocated to the mitochondria,
amplifying the apoptotic signaling pathway. Targeting of these
molecules to mitochondria promotes the liberation of cyto-
chrome c, thus activating the intrinsic apoptotic pathway via
apoptosome formation and caspase-9 activation. The final out-
comes of executioner caspase activation (Fig. 3) are the cleav-
age of specific substrates such as PARP, DNA degradation (Fig.
2), and finally dismantlement of the cell (Figs. 1 and 2), also
manifested in the exposure of phosphatidylserine (Fig. 3). For
the first time, a correlation between calpain cleavage of Bcl-2
and Bid in apoptosis of cancer cells has been demonstrated.
Acknowledgments—We are grateful to Mathias Hafner and Victor
Magdolen for facilitating intracellular activity and calcium meas-
urements or FACS analysis in the laboratories. We also thank Scott
Snipas and Sharon Schendel for the contributions and Dusica
Gabrijelcic-Geiger for the preparation of -calpain. Reinhard Mentele,
Dominique Helmeke, Rita Zauner, Barbara Meisel, and Heide Hinz are
acknowledged for excellent technical assistance.
REFERENCES
1. Raff, M. C. (1992) Nature 356, 397–400
2. Thompson, C. B. (1995) Science 267, 1456–1462
3. Chinnaiyan, A. M., and Dixit, V. M. (1996) Curr. Biol. 6, 555–562
4. Salvesen, G. S., and Dixit, V. M. (1997) Cell 91, 443–446
5. Green, D., and Kroemer, G. (1998) Trends Cell Biol. 8, 267–271
6. Leist, M., and Ja¨a¨ttela¨, M. (2001) Nat. Rev. Mol. Cell. Biol. 2, 589–598
7. Liu, X., Kim, C. N., Yang, J., Jemmerson, R., and Wang, X. (1996) Cell 86,
147–157
8. Adams, J. M., and Cory, S. (1998) Science 281, 1322–1326
9. Hengartner, M. O. (2000) Nature 407, 770–776
10. Berridge, M. J., Lipp, P., and Bootman, M. D. (2000) Nat. Rev. Mol. Cell. Biol.
1, 11–21
11. Youn, H. D., Sun, L., Prywes, R., and Liu J. O. (1999) Science 286, 790–793
12. Wang, H. G., Pathan, N., Ethell, I. M., Krajewski, S., Yamaguchi, Y.,
Shibasaki, F., McKeon, F., Bobo, T., Franke, T. F., and Reed, J. C. (1999)
Science 284, 339–343
13. Furuya, Y., Lundmo, P., Short, A. D., Gill, D. L., and Isaacs, J. T. (1994) Cancer
Res. 54, 6167–6175
14. Molinari, M., Anagli, J., and Carafoli, E. (1994) J. Biol. Chem. 269,
27992–27995
15. Suzuki, K., and Sorimachi, H. (1998) FEBS Lett. 433, 1–4
Ionomycin-activated Calpain in Apoptosis 27225
16. Diaz, F., and Bourguignon, L. Y. (2000) Cell Calcium 27, 315–328
17. Nakagawa, T., and Yuan, J. (2000) J. Cell Biol. 150, 887–894
18. Varghese, J., Radhika, G., and Sarin, A. (2001) Eur. J. Immunol. 31,
2035–2041
19. O’Donovan, C. N., Tobin, D., and Cotter, T. G. (2001) J. Biol. Chem. 276,
43516–43523
20. Knepper-Nicolai, B., Savill, J., and Brown, S. B. (1998) J. Biol. Chem. 273,
30530–30536
21. Porn-Ares, M. I., Samali, A., and Orrenius, S. (1998) Cell Death Differ. 5,
1028–1033
22. Kubbutat, M. H., and Vousden, K. H. (1997) Mol. Cell. Biol. 17, 460–468
23. Bepler, G., Koehler, A., Kiefer, P., Havemann, K., Beisenherz, K., Jaques, G.,
Gropp, C., and Haeder, M. (1988) Differentiation 37, 158–171
24. Gabrijelcic-Geiger, D., Mentele, R., Meisel, B., Hinz, H., Assfalg-Machleidt, I.,
Machleidt, W., Mo¨ller, A., and Auerswald, E. A. (2001) Biol. Chem. 382,
1733–1737
25. McGahon, A. J., Nishioka, W. K., Martin, S. J., Mahboubi, A., Cotter, T. G., and
Green, D. R. (1995) J. Biol. Chem. 270, 22625–22631
26. Potter, D. A., Tirnauer, J. S., Janssen, R., Croall, D. E., Hughes, C. N., Fiacco,
K. A., Mier, J. W., Maki, M., and Herman, I. M. (1998) J. Cell Biol. 141,
647–662
27. Smith, P. K., Krohn, R. I., Hermanson, G. T., Mallia, A. K., Gartner, F. H.,
Provenzano, M. D., Fujimoto, E. K., Goeke, N. M., Olson, B. J., and Klenk,
D. C. (1985) Anal. Biochem. 150, 76–85
28. Goping, I. S., Gross, A., Lavoie, J. N., Nguyen, M., Jemmerson, R., Roth, K.,
Korsmeyer, S. J., and Shore, G. C. (1998) J. Cell Biol. 143 207–215
29. Stoka, V. V., Turk, B., Schendel, S. L., Kim, T. H., Cirman, T., Snipas, S. J.,
Ellerby, L. M., Bredesen, D., Freeze, H., Abrahamson, M., Bromme, D.,
Krajewski, S., Reed, J. C., Yin, X. M., Turk, V. V., and Salvesen, G. S. (2000)
J. Biol. Chem. 276, 3149–3157
30. Xie, Z., and Reed, J. C. (2000) Methods Enzymol. 322, 266–274
31. Hafner, M., Petzelt, C., Nobiling, R., Pawley, J. B., Kramp, D., and Schatten,
G. (1988) Cell. Motil. Cytoskeleton 9, 271–277
32. Stennicke, H. R., and Salvesen, G. S. (2000) Methods Enzymol. 322, 91–100
33. Deveraux, Q. L., Roy, N., Stennicke, H. R., Van Arsdale, T., Zhou, Q.,
Srinivasula, S. M., Alnemri, E. S., Salvesen, G. S., and Reed, J. C. (1998)
EMBO J. 17, 2215–2223
34. Goyal, L. (2001) Cell 104, 805–808
35. Srinivasula, S. M., Ahmad, M., Fernandes-Alnemri, T., and Alnemri, E. S.
(1998) Mol. Cell 1, 949–957
36. Roy, S., Bayly, C. I., Gareau, Y., Houtzager, V. M., Kargman, S., Keen, S. L.,
Rowland, K., Seiden, I. M., Thornberry, N. A., and Nicholson, D. W. (2001)
Proc. Natl. Acad. Sci. U. S. A. 98, 6132–6137
37. Wolf, B. B., Goldstein, J. C., Stennicke, H. R., Beere, H., Amarante-Mendes,
G. P., Salvesen, G. S., and Green, D. R. (1999) Blood 94, 1683–1692
38. Ruiz-Vela, A., Gonzalez de Buitrago, G., and Martinez, A. C. (1999) EMBO J.
18, 4988–4998
39. Chai, J., Wu, Q., Shiozaki, E., Srinivasula, S. M., Alnemri, E. S., and Shi, Y.
(2001) Cell 107, 399–407
40. Riedl, S. J., Fuentes-Prior, P., Renatus, M., Kairies, N., Krapp, S., Huber, R.,
Salvensen, G. S., and Bode, W. (2001) Proc. Natl. Acad. Sci. U. S. A. 98,
14790–14795
41. Ray, S. K., Wilford, G. G., Crosby, C. V., Hogan, E. L., and Banik, N. L. (1999)
Brain Res. 22, 18–27
42. Reed, J. C. (1997) Nature 387, 773–776
43. Zamzami, N., and Kroemer, G. (2001) Nat. Rev. Mol. Cell. Biol. 2, 67–71
44. Thornberry, N. A., and Lazebnik, Y. (1998) Science 281, 1312–1316
45. Huang, Y., and Wang, K. K. (2001) Trends Mol. Med. 7, 355–362
46. Arthur, J. S., Elce, J. S., Hegadorn, C., Williams, K., and Greer, P. A. (2000)
Mol. Cell. Biol. 20, 4474–4481
47. Squier, M. K., and Cohen, J. J. (1997) J. Immunol. 158, 3690–3697
48. Waterhouse, N. J., Finucane, D. M., Green, D. R., Elce, J. S., Kumar, S.,
Alnemri, E. S., Litwack, G., Khanna, K., Lavin, M. F., and Watters, D. J.
(1998) Cell Death Differ. 5, 1051–1061
49. Buki, A., Okonkwo, D. O., Wang, K. K., and Povlishock, J. T. (2000) J. Neu-
rosci. 20, 2825–2834
50. Matsumura, Y., Saeki, E., Otsu, K., Morita, T., Takeda, H., Kuzuya, T., Hori,
M., and Kusuoka, H. (2001) J. Mol. Cell. Cardiol. 33, 1133–1142
51. Sasaki, T., Kikuchi, T., Yumoto, N., Yoshimura, N., and Murachi, T. (1984)
J. Biol. Chem. 259, 12489–12494
52. Saido, T. C., Sorimachi, H., and Suzuki, K. (1994) FASEB J. 8, 814–822
53. Farrow, S. N., and Brown, R. (1996) Curr. Opin. Genet. & Dev. 6, 45–49
54. Yin, X. M., Oltvai, Z. N., Veis-Novack, D. J., Linette, G. P., and Korsmeyer,
S. J. (1994) Cold Spring Harbor Symp. Quant. Biol. 59, 387–393
55. Murphy, K. M., Ranganathan, V., Farnsworth, M. L., Kavallaris, M., and Lock,
R. B. (2000) Cell Death Differ. 7, 102–111
56. Cheng, E. H., Kirsch, D. G., Clem, R. J., Ravi, R., Kastan, M. B., Bedi, A., Ueno,
K., and Hardwick, J. M. (1997) Science 278, 1966–1968
57. Berridge, M. J., Bootman, M. D., and Lipp, P. (1998) Nature 395, 645–648
58. Pinton, P., Ferrari, D., Rapizzi, E., Di Virgilio, F. D., Pozzan, T., and Rizzuto,
R. (2001) EMBO J. 20, 2690–2701
59. Murphy, A. N., Bredesen, D. E., Cortopassi, G., Wang, E., and Fiskum, G.
(1996) Proc. Natl. Acad. Sci. U. S. A. 93, 9893–9898
60. Chen, M., He, H., Zhan, S., Krajewski, S., Reed, J. C., and Gottlieb, R. A. (2001)
J. Biol. Chem. 276, 30724–30728
61. Clem, R. J., Cheng, E. H., Karp, C. L., Kirsch, D. G., Ueno, K., Takahashi, A.,
Kastan, M. B., Griffin, D. E., Earnshaw, W. C., Veliuona, M. A., and
Hardwick, J. M. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 554–559
62. Eto, A., Akita, Y., Saido, T. C., Suzuki, K., and Kawashima, S. (1995) J. Biol.
Chem. 270, 25115–25120
63. Fujita, N., Nagahashi, A., Nagashima, K., Rokudai, S., and Tsuruo, T. (1998)
Oncogene 17, 1295–1304
64. Strack, P. R., Frey, M. W., Rizzo, C. J., Cordova, B., George, H. J., Meade, R.,
Ho, S. P., Corman, J., Tritch, R., and Korant, B. D. (1996) Proc. Natl. Acad.
Sci. U. S. A. 93, 9571–9576
65. Grandgirard, D., Studer, E., Monney, L., Belser, T., Fellay, I., Borner, C., and
Michel, M. R. (1998) EMBO J. 17, 1268–1278
66. Li, H., Zhu, H., Xu, C. J., and Yuan, J. (1998) Cell 94, 491–501
67. Gross, A., McDonnell, J. M., and Korsmeyer, S. J. (1999) Genes Dev. 13,
1899–1911
Ionomycin-activated Calpain in Apoptosis27226
